>>90 million upfront for a drug that doesn't even have phase II data yet. Color me shocked as I did not think they would get anything near this sum, especially given the limited data at hand.<<
The RA data was convincing enough for Incyte's first JAK inhibitor, INCB18424, and everybody knows the company split one drug into two for marketing purposes. Plus I assume Lilly saw some solid interim data from the P2 trial with the 2nd JAK inhibitor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.